DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
28 hedge funds and large institutions have $15.7M invested in DMK Pharmaceuticals Corporation Common Stock in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 2 closing their positions.
4,050% more call options, than puts
Call options by funds: $83K | Put options by funds: $2K
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
12% more funds holding
Funds holding: 25 → 28 (+3)
5% more capital invested
Capital invested by funds: $14.9M → $15.7M (+$805K)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$72.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$69K |
| 3 |
Walleye Trading
New York
|
+$10.4K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$9.65K |
| 5 |
Morgan Stanley
New York
|
+$6.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$500K |
| 2 |
SCM
Sio Capital Management
New York
|
-$288K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$75.4K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$70K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $1K | -$3.93K | -11 | -79% |
|
27
Bank of America
Charlotte,
North Carolina
| $1K | -$715 | -2 | -40% |
|
28
Geode Capital Management
Boston,
Massachusetts
| $254 | – | – | – |
|
|
PAIM
29
Punch & Associates Investment Management
Edina,
Minnesota
| – | -$2.16K | -6 | Closed |
|
30
Group One Trading
Chicago,
Illinois
| – | -$1.07K | -3 | Closed |
|
DMK Hedge Fund Activity: Q1 2016 in Review
28 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2016, worth a combined $15.7M — up 5.4% from $14.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DMK positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 9 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $72.9K. The largest seller was Marshall Wace, cutting an estimated $500K.
- 28 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2016, up from 25 in Q4 2015.
- Funds reported $15.7M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2016, up 5.4% quarter-over-quarter.
- 5 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2016 and 2 closed out, a net change of +3 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2016 was Renaissance Technologies, an estimated $72.9K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2016 was Marshall Wace, an estimated $500K sold.
Based on aggregated 13F filings for Q1 2016.